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Capping of lymphocyte surface Ig is a striking membrane event in which ligands to 
surface Ig cause the rapid redistribution of the receptors to one pole of the cell. Several 
types of evidence indicate that this is a highly organized contractile process:  (a) it is 
energy dependent and is sensitive to cytochalasins (1, 2);  (b) it is associated with the 
mobilization of intracellular calcium (3) and may be blocked by drugs which interfere 
with calcium metabolism (4-6); (c) it involves the formation of a physical interaction 
between surface Ig and  the underlying microfilament network as judged by immu- 
nocytochemical (7,  8), biochemical (9), and  biophysical  (10)  methods;  and  (c)  it is 
accompanied by translatory motion (11),  Furthermore, the capacity of surface Ig to 
associate  with  and  activate  the  contractile apparatus  is  a  restricted  property  not 
shared by other membrane proteins such as the Thy-1 and H-2 alloantigens and the 
heterogeneous group of surface proteins identified by rabbit anti-murine lymphocyte 
antibodies  (ALG) 1 (12).  Capping represents the initial activation phase of a  process 
triggered by surface Ig, which eventually leads to B-cell proliferation and antibody 
secretion (11). 
Recently, methyltransferase reactions have been recognized as an important feature 
in a wide range of contractile processes, including bacterial (13,  14) and mammalian 
(15,  16)  chemotaxis,  lymphocyte-mediated cytolysis (17),  endocrine secretion  (18), 
and platelet aggregation (19).  These studies generally have depended on pharmaco- 
logical  manipulations  that  cause  an  accumulation  of S-adenosylhomocysteine,  a 
strategy based on the strong inhibition exerted by this metabolite, a  product of all 
adenosylmethionine-dependent methylation reactions, on methyltransferases (20).  In 
eukaryotic cells,  S-adenosylhomocysteine is catabolized  to adenosine and  homocys- 
teine by S-adenosylhomocysteine hydrolase;  thus,  by inhibiting  the activity of this 
enzyme, S-adenosylhomocysteine accumulates and, consequently, methyltransferase 
activity falls.  Such inhibition usually has been achieved in two ways: (a) cells may be 
fed  adenosine  and  homocysteine,  particularly  in  the  presence  of agents  such  as 
coformycin or  erythro-9-(2-hydroxy-3-nonyl)adenine  hydrochloride  (EHNA),  which 
prevent the normal, rapid catabolism of adenosine by inhibiting the enzyme adenosine 
deaminase (16);  (b) cells may be treated with 3-deazaadenosine, a potent and specific 
inhibitor of Soadenosylhomocysteine hydrolase. This inhibitor was first characterized 
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by Chiang et al. (21) and has been recently applied to studies with murine lymphocytes 
(17, 22). 
In this paper, we have studied capping of lymphocytes in the presence of these two 
groups  of  inhibitors  and  in  patients  with  a  hereditary  deficiency  in  adenosine 
deaminase.  We have  also tested  the effects of the  inhibitors on  a  contractile event 
directly triggered by the calcium ionophore A-23187. Our results suggest that surface 
Ig capping requires a  methylation reaction which may serve as a  triggering step that 
precedes microfilament activation. 
Materials  and  Methods 
Preparation of Lyrnphocytes.  Murine  lymphocytes were obtained from  2-  to  3-mo-old A/St 
mice (West Seneca Laboratories, Buffalo, N. Y.) using Ficoll (Pharmacia Fine Chemicals, Div. 
of Pharmacia, Inc., Piscataway, N. J.) -Hypaque (Winthrop Laboratories, New York)-purified 
spleen cells. In some cases, thymocytes were also studied; these were teased from the thymus 
and used without further purification. 
Human blood lymphocytes were obtained from normal volunteers, using dextran sedimen- 
tation and  Ficoll-Hypaque centrifugation  (23).  Blood  lymphocytes from  two  patients with 
combined immunodeficiency resulting from adenosine deaminase deficiency were also studied; 
the case histories and related biochemical and functional studies have been reported elsewhere 
(24).  These  patients were  graciously made available to us by Dr.  Arye Rubinstein  (Albert 
Einstein  School  of Medioine,  Bronx,  N.  Y.).  Lymphocytes were  also studied  in  two  other 
patients with adenosine deaminase deficiency who had undergone bone marrow transplantation 
from normal sibling donors 8 yr previously ([25], cases 1 and 2). 
All cell suspensions were >90% viable, as judged by exclusion of trypan blue. 
Reagents 
MEDXA.  All studies were performed in Hanks' balanced salt solution supplemented with 10 
mM Hepes and either 0.5%  bovine serum albumin (for murine lymphocytes) or 2% fetal calf 
serum (for human lymphocytes). 
ANTISERA.  Rabbit  anti-mouse immunoglobulin  antibodies  (anti-Ig), purified by  ion-ex- 
change chromatography and fluorescein conjugated, were characterized previously (12). Rabbit 
anti-human  IgD and IgM were fluorescein-conjugated Fab'2 fragments of purified IgG  (23) 
and used for cell staining as a  1:1  mixture. ALG, purified by precipitation in 50% and 40% 
saturated ammonium sulphate, have been described (3). The anti-Thy-l.2 antiserum (anti-9) 
was prepared by immunization of AK.R mice with CBA thymocytes. This reagent has been 
described (12). The fluorescein-conjugated goat anti-rabbit IgG antibodies were an IgG from 
a goat hyperimmunized to rabbit Ig. The fluorescein:protein ratio was 8.4:1. 
The  conditions  required  to  induce  capping  have  been  described previously and  varied 
according to the type of  surface macromolecule: surface Ig, which caps by apparently interacting 
with  the contractile system, redistributes rapidly following interaction with antibody; ALG 
determinants and the Thy-1 allantigen (O alloantigen) appear to cap simply by forming large 
cross-linked complexes, redistribute slowly and only in a fraction of cells, and require multiple 
layers of antibody to do so (that is, the specific ligand and an antibody to it) (11,  12). Thus, for 
optimal cap formation, we proceeded as follows: (a) surface Ig: 5-10 ×  106 cells were incubated 
with fluorescein anti-Ig (100/xg per ml) for 30 min on ice and rinsed three times in medium at 
0-4°C to remove the unbound ligand. Cap formation generally was induced by incubation at 
20°C rather than at 37°C to slow the capping process and to allow a more accurate measurement 
of this rapid event (4). After 40 min, most cells were capped under these conditions; (b) ALG: 
5 ×  106 cells were stained with ALG (200/~g per ml) for 30 min on ice and rinsed with cold 
medium. Then, the cells were stained with fluorescein-conjugated goat anti-rabbit antibodies 
(.50 ~g per ml)  for 30  min  on  ice and  again rinsed with cold medium.  Cap  formation was 
induced by incubation at  37°C,  yielding ~  50%  capping after prolonged incubation;  (c)  0 
alloantigen: .5-10  ×  106 cells were stained with anti-0 (10% dilution) for 30  min on ice and 
rinsed in cold medium. Then, cells were stained with fluorescein anti-Ig as described above. 
Cap formation was induced by incubation at 37°C, yielding ~  50% capping. 176  DEFECTIVE  CAPPING  IN  ADENOSINE  DEAMINASE  DEFICIENCY 
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F[¢.  1.  Murine lymphocytes were preincubated at 37°C for 60 min with inhibitors, then chilled, 
stained with anti-Ig, and  incubated for 5  min  (O)  or 25  rain  ((3)) at  20°C  to induce capping of 
surface  Ig.  (A)  Homocysteine  (100  /LM),  coformycin  (0.2  #M),  adenosine  (as  indicated);  (B) 
coformycin (0.2/,tM), adenosine (100 #M), homocysteine (as indicated); (C) homocysteine (100/~M), 
adenosine (100 #M), coformycin (as indicated). 
DRUOS.  Adenosine and L-homocysteine thiolactone were purchased from Sigma Chemical 
Co.,  St.  Louis,  Mo.  EHNA  was  purchased  from  the  Bur::oughs  Wellcome  Co.  (Research 
Triangle Park, N. C.). 3-Deazaadenosine was a  generous gift from Dr. Gerald Wolberg of the 
Wellcome Research Laboratories (Research Triangle Park, N. C.). A-23187 was a gift from Eli 
Lilly and Company (Indianapolis, Ind.). Coformycin was a gift from Dr. H. Umezawa (Institute 
of Microbial Chemistry, Tokyo, Japan). 
Experimental Protocol. The effect of the inhibitors on cap formation was tested by preincubating 
5 X  106 cells per 0.5 ml with various agents for 60 min at 37°C. The cells then were pelleted 
and  incubated with appropriate antibodies at 0-4°C.  Finally, the ceils were returned to the 
original volume of medium and drug concentration, incubated for various times to promote 
capping, and fixed with an equal volume of 2% paraformaldehyde to terminate the reaction. 
Cells were scored using a Leitz Ortholux II microscope with epi-illumination (E. Lietz, Inc., 
Rockleigh, N. J.). Cells were considered capped when the fluorescein label was limited to less 
than  one-half of the  cell  surface.  200  or  more  cells  were  scored  for  each  determination. 
Experiments on the patients with the adenosine deaminase deficiency were performed on only 
one occasion. Otherwise, experiments were performed on at least three different occasions with 
the same results. 
Results 
Effect of Inhibitors of Methylation on Cap Formation.  The effect of inhibitors was tested 
on capping of surface Ig by preincubating murine or human lymphocytes with various 
concentrations of adenosine, homocysteine, and coformycin. Fig. 1 shows results using 
murine lymphocytes. Separately, each of these agents had no effect on capping in the 
concentration  range of 1-500/~M  for adenosine and homocysteine and  1 nM-2  #M 
for coformycin. However, in combination, they inhibited capping in a dose-dependent 
fashion. Comparable results were found when coformycin was replaced by EHNA: in 
the  presence  of EHNA  (10  /~M)  and  homocysteine  (100  #M),  adenosine  inhibited 
capping by 20  and  100%  at  concentrations of 10  and  100 ~M,  respectively. Similar 
results  were  obtained  with  human  lymphocytes.  Fig.  2  illustrates  a  representative 
experiment on  lymphocytes from  a  normal human  volunteer. As before, each  agent 
separately had  little effect  on  capping;  also,  in  combinations  of two  agents,  little 
inhibition  occurred.  However,  a  combination  of all  three  agents  totally abolished 
capping. 
Deazaadenosine caused a dose-dependent inhibition of cap formation, and this was 
potentiated  10-fold in the presence of 100/IM  homocysteine  (Fig. 3).  These concen- JONATHAN  BRAUN,  FRED  S.  ROSEN,  AND  EMIL R.  UNANUE  177 
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Fro. 2.  Human  blood lymphocytes from a  normal  volunteer  were preincubated for 60 rain  at 
37°C, then chilled, stained for surface Ig, and incubated for 10 minutes at 37°C to induce capping+ 
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Fro. 3.  Murine lymphocytes were preincubated at  37°C  for 60  min with deazaadenosine  and 
homocysteine, then chilled, stained with anti-Ig, and allowed to cap at 20°C for 20 min. (A) the 
dose response to deazaadenosine in the presence of homocysteine at 0 ~M (0) or at 100 p.M (O); (B) 
dose response to homocysteine in the presence of deazaadenosine at 0/zM (0), 0.25 #M (C)), or 1.25 
~M (A). 
tration  ranges  were  comparable  to  those  required  for  inhibition  of  lymphocyte- 
mediated cytolysis (17)  and  chemotaxis  in  monocytes  (16)  and  in neutrophits  (22). 
They  also corresponded  to  the  range  required  for  the  inhibition of methylation  in 
lymphocytes when measured by direct biochemical methods  (17, 22). 
These initial results demonstrated that both sets of agents were potent inhibitors of 
surface Ig capping but raised two issues: (a) the drug effects could have involved a cell 
process not directly related to contractile mechanism; (b) the perturbation of adenosine 
metabolism induced by these drugs could have inhibited capping through  a  mecha- 
nism different from methylation (26). 
To  test  for  the  specificity of these  agents  for  the  contractile process  involved  in 
capping of surface |g, we examined, for comparison, the capping of the 0 alloantigen 
and  ALG  determinants.  This  class  of surface  macromolecule  caps  in  an  energy- 
dependent  fashion  (11)  but  by  a  mechanism  apparently  unassociated  with  the 
contractile apparatus  (12).  (The studies were done only in the mouse because of the 
more extensive experience with various plasma membrane proteins in this species.) In 
Fig. 4,  concentrations  of adenosine,  homocysteine, and  coformycin that  completely 
abolished capping of surface Ig had little effect on the relatively inefficient capping 
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FIG.  4.  Murine lymphocytes were preincubated at 37°C for 60 rain with inhibitors, then chilled, 
stained  with  appropriate  reagents,  and  capped  under  optimal  conditions  to  promote  capping 
(Materials  and Methods).  (A)  capping after 5  rain;  (B)  capping after  25  min. Note  the relative 
insensitivity of 0 alloantigen and ALG determinants capping to inhibitors. 
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Murine lymphocytes were treated with inhibitors and capped for 25 rain as in Fig. 4. 
osine and homocysteine, which well exceeded the levels necessary to block surface Ig 
capping, had no effect on capping of the other class of surface macromolecules (Fig. 
5). 
In other experiments, the effects of ethionine and amethopterin were tested on cap 
formation. However, these agents were highly toxic at inhibitory concentrations  (>1 
mM) and were deemed unsuitable for further study. 
Effect of Inhibitors of A-23187-induced Cap Disruption.  The inhibition  of Ig capping 
suggested that  the  inhibitors  might  be exerting their effect on  the cells' contractile 
apparatus. This possibility was tested using A-23187-induced  cap disruption. In cells 
which  have already formed caps, exposure to A-23187,  a  calcium ionophore, causes 
the caps to reverse in a process requiring extracellular calcium and metabolic energy 
(4)  and  associated with  remarkable arrays of hypercontracted  microfilaments  (27). 
On  the  basis  of these  observations,  A-23187-induced  cap  disruption  is  believed  to 
represent a direct and global activation of the microfilaments. Therefore, cap disrup- 
tion was used to test for a direct effect of the inhibitors on contractile activation. Cells 
were incubated with anti-Ig at 20°C for 20 rain to allow cap formation, treated with 
drugs  for an  additional  20  rain,  and  finally  treated  with  A-23187  for  10  rain  to 
produce  cap disruption  (Table  I).  As expected,  deazaadenosine  and  homocysteine 
blocked the additional cap formation which occurred between 20 and 50 min (64 and 
95%,  respectively); however, the agents did not protect the cells from cap disruption 
by  A-23187.  Thus,  these  inhibitors  did  not  appear  to  act  directly  on  contractile JONATHAN BRAUN, FRED S. ROSEN, AND EMIL R.  UNANUE 
TABLE I 
Effect of Deazaadenosine and Homocysteine on A-23187-induced  Cap 
Disruption 
Capping time  A-23187 
Deazaadenosine 
0 #M  0.1/LM  1.0/IM 
m~  tlgper ml  % 
20  0  64  --  -- 
50  0  95  65  62 
50  0.1  60  43  18 
50  1.0  10  7  2 
Cells  labeled  with  anti-Ig  were  incubated  for  20  min  at  20°C  to  induce 
capping. Deazaadenosine and homocysteine (300 ~M)  were then added,  and 
the cells were incubated for an additional 20 min. A-23187  was added for the 
last  10 min to disrupt the formed caps. Values represent percent caps among 
Ig-positive cells.  Note  that  deazaadenosine  and  homocysteine blocked  the 
additional  cap formation that occurred between 20  and 50  min but did  not 
prevent cap disruption induced by A-23187. 
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Fie.  6.  Human blood lymphocytes were incubated for 120  rnin at 37°C at a  cell  density of 2 × 
106 per ml (0) or 6  ×  10  v per ml (O).  Cells were then incubated for surface Ig and incubated for 
various times to promote capping. (A) Results from two different patients with hereditary deficiency 
in adenosine deaminase. In both groups, the incubation with anti-Ig antibodies and the capping 
stage were carried out at the same cell concentration (106 per ml). (B) Results from two representative 
normal children. 
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activation but rather at some point preceding contraction, which was circumvented 
by the ionophore. 
Capping  in  Patients  with  a  Hereditary  Deficiency  in  Adenosine  Deaminase.  Studies  of 
capping in the patients with adenosine deaminase deficiency were performed in cells 
preincubated at  two cell densitities,  based  on  the  following reasoning:  at  low cell 
density, adenosine might be released by cells and be diluted efficiently by the bathing 
medium,  thus dissipating the intracellular levels of adenosine;  at high cell density, 
adenosine would not be diluted efficiently by the medium, and levels of intracellular 
adenosine would accumulate.  In  Fig.  6, lymphocytes from normal children capped 
rapidly and were unaffected by their preincubation at different cell densities; similar 180  DEFECTIVE CAPPING IN ADENOSINE DEAMINASE DEFICIENCY 
results  were  found  with  all  five of the  other  normal  subjects  tested.  In  contrast, 
lymphocytes from the two patients with adenosine deaminase deficiency capped less 
efficiently. This defect was already evident in cells preincubated at low cell density 
and quite poorly after the brief incubation at high cell density. Notably, capping was 
normal  in  the two patients who previously had undergone successful bone marrow 
transplantation:  >90%  capping occurred after  10 rain  in  lymphocytes precultured 
either at low or high cell density. 
Discussion 
Our results indicate that putative inhibitors of methylation interfere with capping 
of surface Ig but  not  of other surface macromolecules. Experiments with  A-23187 
suggest that the sensitive step occurs in the signalling phase which precedes contractile 
activation. Also, a related capping defect appears to exist in patients with a deficiency 
in adenosine deaminase. 
The capacity of surface Ig to interact with the contractile apparatus is an important 
feature  that  distinguishes  it  from  the  family of surface  protein  exemplified by  8 
alloantigen and ALG determinants.  Thus, triggering of microfilament activity may 
be the process affected by the alleged inhibitors of methylation tested in this paper. 
The effect of these different agents was not simply a result of the inhibition of energy 
metabolism,  because  such  an  occurrence also  would  have  inhibited  capping  of 8 
alloantigen and ALG determinants. In addition, the combination of deazaadenosine 
and homocysteine at these concentrations does not affect the levels of ribonucleotide 
triphosphates  in  murine  lymphocytes (22).  Furthermore,  abnormal  levels of cyclic 
nucleotides were unlikely to mediate the drug effects for three reasons:  (a) increasing 
cyclic AMP by exposure to permeable cyclic nucleotide analogues, with or without 
phosphodiesterase inhibitors, does not influence capping of surface Ig (11);  (b) high 
doses of concanavalin A  inhibit capping as a  result of microtubule polymerization 
that  may  be  induced  by  excessive  intracellular  levels  of cyclic  nucleotides,  such 
inhibition is reversed by colchicine (11).  However, colchicine does not protect cells 
from the inhibition of capping caused by the inhibitors used in this paper (data not 
shown).  (c)  Deazaadenosine  and  homocysteine  do  not  affect  the  levels  of cyclic 
nucleotides in lymphocytes (22). 
Studies with A-23187 suggested  that  the inhibitors acted at a  step that  precedes 
contractile activation per se. In this regard, it is interesting to note that, in monocytes, 
methylation  inhibitors  appear  to  block chemotaxis  but  not  phagocytosis  (16).  As 
suggested by Pike et al.  (16), certain receptors might  trigger contraction through a 
methylation-dependent signal that precedes contraction itself. 
In lymphocytes, the earliest known event generated by ligands to surface Ig is the 
mobilization of intracellular calcium (3).  Recently, the effect of deazaadenosine was 
tested on this ionic event;  however, no influence on calcium mobilization could be 
demonstrated (Unpublished experiments.). The inhibitor-sensitive step thus is separate 
from, and  may be subsequent  to,  the  initial  ionic event on capping.  The possible 
relationship  between  this  ionic  event  and  the  putative  methylation  reaction(s)  is 
currently under study. 
Studies in the patients with  the adenosine deaminase deficiency demonstrated a 
defect in capping apparently as a result of accumulation of an inhibitory substance, JONATHAN BRAUN, FRED S.  ROSEN, AND EMIL R. UNANUE  181 
presumably involving adenosine or a related metabolite like S-adenosylhomocysteine 
and possibly caused by a secondary inhibition of methylation. The possible importance 
of abnormal  methylation in  adenosine deaminase  deficiency has  been  emphasized 
elsewhere (28).  However, support of this interpretation awaits direct measurement of 
methyltransferase activity under these culture conditions and a better understanding 
of methylation reaction required for capping of surface Ig. 
These studies  suggest  the  presence of an  early methylation reaction required  to 
trigger surface Ig capping.  What  might  be the nature of this possible methylation 
step? In bacteria, the substrate for methylation is a class of proteins associated with 
but  distinct  from  the  chemotactic  receptors  (13,  14).  In  neutrophils,  chemotactic 
agents stimulate a rise in carboxymethylation that is inhibitable by the appropriate 
inhibitors;  however, this has not been demonstrated in monocytes. In macrophages 
and in neutrophils, chemotactic agents may induce a change in the levels of methyl- 
ated lipids (29, 30), although their identities and their relationship to the mechanism 
sensitive to methylation inhibitors is unclear. It is indeed intriguing to consider the 
possible role of methylation-induced membrane structural changes (31) on the protein- 
protein interactions that  constitute surface redistribution  and  cell motility.  In  this 
regard, we are investigating methylation reactions in lymphocytes. Aside from con- 
firming that  the inhibitors used here do inhibit  lipid methylation, we have yet no 
definite indication that this process is the crucial biochemical event. 
The manner in which adenosine deaminase deficiency in man causes the diverse B- 
and T-cell dysfunctions is not apparent. However, it is likely that a defect in capping 
may  reflect  a  more  general  impairment  of membrane  function,  which  could  be 
responsible for the inability of the affected cells to properly mature and respond to 
antigenic stimuli.  Finally, the correction of the capping defect in the transplanted 
patients is of interest. It could indicate that  the B lymphocytes were normal and of 
donor origin; alternatively, normal capping could have resulted from removal of toxic 
metabolites by the transplanted cells (31). 
Summary 
Capping  of membrane  Ig  was  studied  in  lymphocytes treated with  agents  that 
interfere with  adenosine metabolism.  Treatment of murine or human  B  cells with 
combinations of coformycin, an inhibitor of adenosine deaminase, homocysteine, and 
adenosine  impaired  Ig  capping.  Inhibition  of capping  was  also  produced  by  3- 
deazaadenosine, a  specific inhibitor of adenosylhomocysteine hydrolase. The inhibi- 
tors did not affect capping of the Thy-1 antigen or membrane sites reactive with anti- 
lymphocyte  antibodies.  Two  patients  with  a  hereditary  deficiency  in  adenosine 
deaminase  had  impairment  of Ig capping.  Such  an  impairment  was  not  found in 
lymphocytes  of two  other  patients  who  had  undergone  successful  bone  marrow 
transplantation. 
It  is  known  that  the  addition  of a  calcium  ionophore  results  in  activation  of 
micro  filament function and  in disruption of Ig caps. The ionophore effect was  not 
inhibited by the agents mentioned above. Our results suggest that the inhibition of Ig 
capping  during  aberrant  adenosine  metabolism  may be  caused  by  a  methylation 
defect preceding the contractile event that produces membrane reorganization. 
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